Mikhail Blagosklonny is currently professor of Oncology at the Roswell Park Cancer Institute. He was appointed to this position since 15th April 2009. Prior to this coveted appointed he was a Senior Scientist at the Ordway Research Institute in Albany, New York.
Shortly before he took up this job in the year 2002, he was appointed Associate Professor of Medicine at New York Medical College situated at Valhalla in New York.He is an Editor-in Chief of Oncotarget. He also seats in the journal’s Editorial Board of Cell Death and Differentiation.
He is also an Associate Editor of Cancer Biology and Therapy of the same journal. He doubles up as the Founder Editor and Editor in Chief of Cell Cycle journal.Mikhail Blagosklonny is an alumnus of First Pavlov State Medical University of St Petersburg. He graduated with an M.D. in Internal Medicine and a PhD in Experimental Medicine and Cardiology. He is well known for his role in TOR signalling in aging and cancer.
View Mikhail’s profile in LinkedIn
He is even more renowned for his advocacy of the use of the cancer drug Rapamycin for possible longevity of life. He has done a lot of research on cancer and target cancer therapies. He has done research on Biogerontology (Mechanisms of Aging) and has proposed Rapamycin as an anti-aging drug.
He holds many publications under his name. He has published more than 270 papers. He is recorded as having used more than 25,000 citations. He thus holds an h-index of 83.From the foregoing, it is clear that Mikhail Blagosklonny is an accomplished Physician, Scientist and Professor of Medicine and Oncology.
He has risen through the ranks with various top-notch appointments. He now holds the position of Professor of Oncology at the Roswell Park Cancer Institute. He continues to write more publications having written more than 270 paper hitherto. He is passionate in Bio gerontology and has even proposed use of Rapamycin to elongate life.
Follow Mikhail on Loop